Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study to Evaluate Initiation of Stalevo in Early Wearing-off (SENSE)

This study has been completed.
Information provided by:
Orion Corporation, Orion Pharma Identifier:
First received: April 17, 2007
Last updated: April 20, 2015
Last verified: April 2015
An open, non-randomised, multinational, multicentre direct switch study in levodopa-treated Parkinson's disease patients suffering from early wearing-off in Parkinson's disease. The study will consist of 2 consecutive periods: screening period and study treatment period. Duration of the study will be up to 8 weeks for each subject. The study treatment dosage will be determined by the subject's current, separately administered standard levodopa/DDCI treatment (3-4 doses per day, maximum of total daily dose of 600 mg levodopa) which will be switched to an equivalent dose of Stalevo® without changing the number of doses per day. The levodopa daily dose during Stalevo® treatment may be adjusted according to the study subject's clinical response.

Condition Intervention Phase
Parkinson's Disease
Drug: Stalevo
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Stalevo® in Subjects With Early Wearing-off Identified Using a Screening Tool WOQ-9; an Open, Non-randomised, Multinational, Multicentre 6-week Direct Switch Study in Levodopa-treated Parkinson's Disease Patients

Resource links provided by NLM:

Further study details as provided by Orion Corporation, Orion Pharma:

Primary Outcome Measures:
  • Clinical Global Impression of Change (Patient) [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • Clinical Global Impression of Change (Investigator); United Parkinson's Disease Rating Scale (II, III); Quality of Life Visual Analogue Scale; Wearing-off Questionnaire with 9 symptoms [ Time Frame: 6 weeks ]

Enrollment: 115
Study Start Date: September 2006
Study Completion Date: December 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: Stalevo
Oral 3-4 daily doses for 6 weeks

Detailed Description:
See 'Brief summary'.

Ages Eligible for Study:   35 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with idiopathic Parkinson's disease and early wearing-off symptoms treated with standard levodopa/DDCI treatment
  • Age >35 - years
  • Hoehn and Yahr stage 1-3 performed during the 'ON'-stage
  • At least 1 symptom identified by WOQ-9
  • Dosing frequency of 3-4 doses of standard-release levodopa/DDCI (maximum total daily dose of 600 mg of levodopa)

Exclusion Criteria:

  • Atypical or symptomatic Parkinson's disease
  • Unpredictable OFF-periods
  • Any peak-dose dyskinesia. 'OFF'-state dystonia is allowed
  • Use of any rescue medications to treat symptoms of 'OFF'-state. 1 dose of soluble levodopa/DDCI is allowed.
  • Concomitant treatment with non-selective monoamine oxidase (MAO) inhibitor or simultaneous use of higher than recommended doses of MAO-A and MAO-B inhibitors (selegiline 10 mg or rasagiline 1 mg allowed) or use of apomorphine.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00462007

Humboldt Universität Charité Neurologische Klinik
Berlin, Germany, 10098
St. Josef-Hospital, Klinikum der Ruhr-Universität-Bochum Neurologische Klinik
Bochum, Germany, 44791
Pharmakologisches Studienzentrum Chemnitz
Chemnitz, Germany, 09111
Universitätsklinikum Carl Gustav Carus Klinik und Poliklinik für Neurologie
Dresden, Germany, 01307
Gemeinschaftspraxis für Neurologie & Psychiatrie
Erbach, Germany, 64711
Neurologische Praxis Dr Christine Schuster
Giessen, Germany, 35390
Universitätskrankenhaus Eppendorf
Hamburg, Germany, 20251
Paracelsus-Elena Klinik
Kassel, Germany, 34128
Krefeld, Germany, 47805
Nervenarztpraxis Dr Alexander Nass
Köln, Germany, 51069
Universitätsklinikum Gießen und Marburg GmbH
Marburg, Germany, D-35039
Asklepios Fachklinikum Stadtroda
Stadtroda, Germany, 07646
Eberhard-Karls-Universität, Universitätsklinikum Tübingen, Zentrum für Neurologie
Tübingen, Germany, 72076
Neurologische Klinik der Universität Ulm
Ulm, Germany, 89081
Länsjukhuset Ryhov, Geriatriska Kliniken
Jönköping, Sweden, 55185
Nyköpings Lasarett, Ger/Rehabkliniken
Nyköping, Sweden, 61185
Visby lasarett, Neurologmottagningen
Visby, Sweden, 62184
United Kingdom
The Royal Bournemouth Hospital, Department of Medicines for the Elderly
Bournemouth, Dorset, United Kingdom, BH7 7DW
North Tyneside General Hospital, Department of Medicine
North Shields, Tyne and Wear, United Kingdom, NE29 8NH
Royal Sussex County Hospital, Neurology Department
Brighton, United Kingdom, BN2 5BE
Sponsors and Collaborators
Orion Corporation, Orion Pharma
Principal Investigator: Wolfgang H. Oertel, Professor Universitätsklinikum Giessen und Marburg GmbH
  More Information

Responsible Party: Liisa Luotonen, Orion Pharma Identifier: NCT00462007     History of Changes
Other Study ID Numbers: 2939117
Study First Received: April 17, 2007
Last Updated: April 20, 2015

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases processed this record on April 28, 2017